Toshihide Takeuchi, Kazuhiro Maeta, Xin Ding, Yukako Oe, Akiko Takeda, Mana Inoue, . . . Yoshitaka Nagai. (2023). Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice. Elsevier.
Chicago Style (17th ed.) CitationToshihide Takeuchi, et al. Sustained Therapeutic Benefits by Transient Reduction of TDP-43 Using ENA-modified Antisense Oligonucleotides in ALS/FTD Mice. Elsevier, 2023.
MLA (9th ed.) CitationToshihide Takeuchi, et al. Sustained Therapeutic Benefits by Transient Reduction of TDP-43 Using ENA-modified Antisense Oligonucleotides in ALS/FTD Mice. Elsevier, 2023.
Warning: These citations may not always be 100% accurate.